Dr. Brian Morin is currently President & COO of Dreamweaver International, a company that developing and marketing a high performance battery separator that can reduce the volume, weight and cost of lithium ion batteries while improving the safety during thermal events.
Brian also serves on several boards and foundations, including the External Advisory Board for the Clemson University Department of Materials Science and Engineering, the Foundation Board for the North Carolina School of Science and Mathematics and as Vice President of the National Alliance for Advanced Technology Batteries.
I hold a Graduate Diploma in Applied Finance and Investment (similar to CFA), and a Graduate Diploma in Financial Planning.
I have 30 years of personal investing experience, and 15 years of professional financial advising experience, including broking experience at ETrade Australia, 7 years as a Senior Financial Planner at Commonwealth Bank of Australia and 8 years at High Net Worth Financial Advising. My business is a mix of young clients growing their wealth, pre-retirees, and retirees wanting income, some growth, and safety.As a global investor I use a macro thematic approach searching for good value and/or high growth. I search the globe for great investments with a focus on Asia, Emerging and Frontier Markets as well as "trend investing". I assess a countries demographics and growth potential. Some trends I currently follow include Chinese shares going global, the rising Asian middle class, Electric Vehicles, Renewable Energy, Energy Storage, Smartphones, 3D printing, and personal robots.
I also love to invest in income producing investments that can grow over time and benefit from compounding....Included here are the near monopoly businesses such as the Stock Exchanges, and the high quality income producers.
I use direct shares, ETFs, mutual funds and some direct property investments.
Tomasz Tunguz is a Partner at Redpoint Ventures where he works with Axial, Looker, Electric Imp, Expensify, ThredUp, Quantifind and Erply. He blogs at www.tomtunguz.com
Prior to joining Redpoint, Tomasz was the Product Manager for Google's Social Media monetization team, including the Google-MySpace partnership. In addition, he managed the launches of AdSense into six new markets in Europe and Asia. Before Google, Tomasz developed systems for the Department of Homeland Security at Appian Corporation, a provider of Business Process Management solutions. Tomasz also co-founded Perquimans Systems, a provider of bilingual, tri-currency automated time billing and document management systems for top tier law firms in Chile.
Tomasz holds a B.A. in Mechanical Engineering, a B.E. in System Identification and Control Systems and Master of Engineering Management from Dartmouth College where he was a George Revitz Fellow.
Specialties: Social networking, monetization, enterprise systems architecture, machine learning, business process management, mobile web
Kim Klaiman is a full time options trader and founder of SteadyOptions.com. He trades mostly non-directional strategies, like pre-earnings strangles and iron condors. Likes to trade strategies with negative correlation. He lives in Toronto, Canada. Visit the SteadyOptions.com forum. SteadyOptions offers a combination of a high quality education and actionable trade ideas using variety of Non-Directional option trading strategies for Steady and Consistent Profits. Email: firstname.lastname@example.org Follow me on Twitter: https://twitter.com/SteadyOptions_ SteadyOptions performance: https://steadyoptions.com/performance
Mid Market M&A consultant specializing in technology and energy industries. Individual Investor for over 25 years. Growth oriented investments primarily in market leaders and technology leaders. Investment philosophy is long term buy and hold with average holding time of several years.
I have a keen sense of cutting through management and Investment banker commentary and seeing true value of companies. A lot of my views tend to be controversial for that reason but at the same time remarkably accurate.
To get a feel for my writing, readers can puruse a few of my recent against the grain calls:- with extremely high success rates.
Steven H. Goldman is a commercial litigation lawyer and senior partner in the Toronto law firm of Goldman Hine LLP. He is a former member of the board of directors of Tribute Pharmaceuticals Inc., a Canadian public pharmaceutical company which recently merged with Pozen Pharmaceuticals on February 5, 2016, and is now known as Aralez Pharmaceuticals (Nasdaq: ARLZ). He is currently on the board of directors of both Select Sands Corp. (TSX.V: SNS.V) as well as Comstock Metals Ltd. (TSX.V: CSL.V) which both trade on the TSX Venture exchange.
Avi Gilburt is a lawyer and accountant by training. He formerly was a partner and National Director at a national firm.
Mr. Gilburt is also the Managing Member of Gilburt Financial Services, LLC, which provides:
- Financial market analysis to the public through ElliottWaveTrader.net;
- Elliott Wave market analysis to institutional clients;
- Specific stock analysis to retail clients; and
- Webinars and personal coaching on Elliott Wave analysis.
He is also the Managing Member of the of the consulting firm of Gilburt & Associates, LLC, which specializes in transaction structuring and tax services.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
I focus on investments in the oil & gas & MLP sectors with an eye for dividend income growth and long-term capital appreciation. I typically allocate a portion of my own portfolio and devote some of my Seeking Alpha articles to small and medium sized companies offering compelling risk/reward propositions. I am an engineer, not a qualified investment advisor. While the information and data presented in my articles are obtained from company documents and/or sources believed to be reliable, they have not been independently verified. Therefore, I cannot guarantee its accuracy. I advise investors conduct their own research and/or consult a qualified investment advisor. I explicitly disclaim any liability that may arise from investment decisions you make based on my articles. Thanks for reading and I wish you much success with your investments.
I currently work in the health care field. I am a long-term investor who conducts extensive research as part of my due diligence when considering a stock. My articles hope to provide unbiased background information to help others make an educated decision.
Although I recommend a diversified portfolio, I have a special interest in biomedical firms. Since biomedical investing is often very risky, I believe that research is especially important when investing in this industry. I find biomedical investing rewarding because these investments may not only yield high returns but also help save lives.
Bay Area Biotech is a group of self-organized life science graduate/medical/business students and postdoctoral scholars who are interested in utilizing our scientific training to evaluate biotechnologies and identify investment opportunities. Opinions published here are those of the authors.
I took my writing, research, and marketing skills and created my own Internet Marketing Services company, Cilderman Solutions, LLC.
www.CildermanSolutions.com - I hope you will stop by!
Stephan Bogner is mining analyst at Rockstone Research, he has independently analyzed capital markets and resource stocks for more than 11 years. He is also CEO at Elementum International AG of Switzerland trading precious metals and storing them in a high-security vaulting facility within the St. Gotthard Mountain Massif in Central Switzerland which is a duty-free zone. Bogner earned his degree in economics in 2004 at the International School of Management in Dortmund, Germany. He spent five years in Dubai brokering and reselling physical commodities and now resides in Zurich, Switzerland.
Diplom-Kaufmann Stephan Bogner began his academic studies in economics at the International School of Management in Dortmund (Germany) and was one of many who was hooked by the thrilling lectures of Professor Bocker on economic and monetary systems. Yet he was (and still is) the only student of the university that wrote a diploma thesis on precious metals as a protection against inflation (“Gold in a macroeconomic context with special consideration of the price formation process”) that was completed in 2002 under the supervision of Professor Bocker. Mr Bogner specialised in Finance & Asset Management, Production & Logistics and International Law & Entrepreneurship. He also studied at the European Business School in London (UK) and the University of Queensland in Brisbane (Australia).
In 2003, he started working closely with Ferdinand Lips, among others to publish and market his latest bestseller (“Gold Wars – The Battle Against Sound Money As Seen From A Swiss Perspective“) in the German-speaking countries. He revised and translated the English version into German (“Die Gold Verschwörung”). In 2004, he went to work at the biggest gold market in the world (Dubai), where he started up two companies that were specialised in re-selling and brokering physical commodities and consulting with publicly-listed mining companies. Moreover, he was co-founder and, until late 2006, partner of the first German silver stockletter and online information platform (Silberinfo.com) besides dealing with coins and bars.
Mr Bogner is an active analyst for several research firms, institutional and private investors and family offices, mainly for the analysis and valuation of capital markets and publicly-listed companies with a focus on geology, exploration, development and production of resource deposits. Since years, he lives in Zurich (Switzerland) and regularly publishes articles in German and English about economic contexts, currencies, commodities and companies active in exploration and mining of natural resources worldwide.
Full Time Micro Cap Investor. Founder of MicroCapClub.com
Founded in 2011, MicroCapClub is an exclusive forum for experienced microcap investors focused on microcap companies (sub $300m market cap). MicroCapClub was created to be a platform for experienced microcap investors to share and discuss stock ideas. MicroCapClub’s mission is to foster the highest quality microcap investor Community, produce Educational content for investors, and promote better Leadership in the microcap arena.
Ian Wyatt is an active investor, a well-regarded investment expert and an Internet entrepreneur. He is the Chief Investment Strategist at Wyatt Investment Research, and plays a leading role in each of the company’s investment newsletters and trading services.As a well-regarded market expert, Ian has written for Marketwatch, Zacks Investment Research, Seeking Alpha, Yahoo! Finance and The Burlington Free Press. He has been interviewed or quoted in articles in well-known publications including AOL Finance Blogging Stocks, Kiplinger’s Personal Finance Magazine, Barron Magazine, Barrons.com, Forbes.com, The Dick Davis Digest, The Dick Davis Income Digest, The Wall Street Transcript, TheStockAdvisors.com, Money Show Digest, The New Jersey Star Ledger, The Wisconsin State Journal and The Seattle Times.
In 1998, Ian combined two of his passions, stocks and the Internet, with the launch of a free investment web site with expert advice about investing in stocks.
Ian founded Business Financial Publishing and Wyatt Investment Research in 2001, publishing investment newsletters for individual investors. Since then, the company has evolved into an Internet content company publishing e-letters, special reports, newsletters, trading services and financial web sites.
Business Financial Publishing was named #185 on the 2008 Inc. Magazine Inc. 500 list of the fastest growing companies in the United States, achieving a 3-year growth rate of 1,303%. The company currently reaches over one million individual investors weekly through its free e-letters.
His first book, The Small-Cap Investor: Secrets to Winning Big with Small-Cap Stocks, was published by John Wiley & Sons in September 2009. Ian lives in the Green Mountains of Vermont with his wife Carrie.
Nathan Weiss is the Senior Analyst and company founder of Unit Economics, a Boston-based independent research firm. Nathan Weiss was the author of The Weiss Report, a monthly newsletter focused on risk arbitrage and market neutral strategies from 1998 to 2000. From 2000 to 2006 Mr. Weiss was a generalist analyst and portfolio manager at Noble Partners, contributing significantly to their outstanding returns.
Zack Buckley is the founder and President of Buckley Capital Partners, a value-focused long/short equity hedge fund. BCP employs a fundamental approach that is research intensive and concentrated, generally with 10-15 core positions focused primarily in small cap equities. While BCP is long-biased, the fund occasionally shorts companies in situations with highly asymmetric risk-reward potential. Mr. Buckley is a contributing writer for Thestreet.com and Seekingalpha.com. Prior to launching Buckley Capital Partners, Mr. Buckley was an analyst at Baker Street Capital Management.
Managing partner at Sand Hill East (www.sandhilleast.net), a VC advisory/investment firm specializing in aiding early stage technology companies.
Started career at Goldman Sachs as research analyst. Worked 10 years on the buyside primarily at Moore Capital and offshoot Pia Capital.
Private Investor with 10 years of biotech trading experience.
I use basic disciplined research approach to discover new investment ideas. Biotech sector is full of violent stock moves and trial failures. On one hand it requires traders to be quick on their feet and on the other hand it forces investors to have a great deal of patience.
I enjoy the challenge of mining for hidden gems, because its 10 times as hard to do that than predicting failures. Failure is the norm in biotech, I look for exception to the norm!
Malcolm holds a MSc in Geology and has 13 years of experience spanning the resource and investment industries. He started his career as a geoscientist at PanCanadian Petroleum (now EnCana) before transitioning into the investment industry as an international energy research analyst at Wellington West Capital Markets. Before joining Hydra Capital, Malcolm was a Vice President at K2 & Associates Investment Management where he focused on the energy and materials sectors.
Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an senior equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science.
Grant Zeng obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China.
Grant Zeng is a Chartered Financial Analyst (CFA) charter holder.
Author of the critically acclaimed book, "Taking Charge With Value Investing (McGraw-Hill, 2013)" and the premium subscription service "Tipping The Scale" (as seen below). An analyst that ranks in the top 4% on both tipranks.com and Motley Fool CAPS for stock picking performance.
Tipping the Scale members gain access to the TTS Portfolio Tracker. Here, members see what I am buying and selling the minute it happens, along with what I have owned, bought, and sold historically. These are just a few of the features on the TTS Portfolio Tracker.
Tipping The Scale is an equity research platform that uses a numeric scale instead of the traditional "Buy, Hold, Sell" to identify the best investment opportunities in the market. Stock coverage is determined by market catalyst, and every company goes through a vigorous test in 10 different categories. The higher the total score, the bigger the upside. In addition, Tipping the Scale also provides a number of portfolio strategies to hedge the volatility of the market and protect from downside.
Check out my instablog for more information on the popular research service Tipping the Scale, including performance information, benefits, and how it all works.
Roy Manning is an investor who attended college at SUNY(studied Pre-med) and then University of Wisconsin (studied banking, development planning and real-estate accounting). I am currently focusing on screening stocks in the Biotech, Pharmaceutical and Mining Stocks areas. I wish everyone success in investing.
Red Acre applies value investing principles to mirco-cap and binary event investing.
Our Chief Investment Officer is Rajesh Patel. Prior to Red Acre, Rajesh was a Member of Technical Staff with the Massachusetts Institute of Technology, (MIT) Lincoln Laboratory where he analyzed the strategic value of emerging technologies to enhance the capabilities of the U.S. Military. Rajesh holds a Ph.D. in Applied Physics from the University of California, Davis, a Master's in Environmental Science from Rice University and bachelors degrees in both Physics and English from the University of Connecticut.
Red Acre's investment style is to look for opportunities where the intrinsic value of a stock is likely to go through a dramatic transition due to some future event about which we can predict an outcome relying on our research and due diligence experience. We are patient investors and are comfortable with having time horizons of several months to over a year for our investment thesis to fully play out.
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy
I am currently employed by a Fortune 20 company, on any given day I am assessing risk management and the financial health of various companies. My time is spent looking at charts and numbers all day and I specialize in statistical analysis. I use the writers of various finance sites for my investing ideas, then do my own research prior to investing.
Thanks to those of you that have given me feedback and responded to my messages. I have found the writers at Seeking Alpha to be very accommodating and informative.